thought call
ep beat modest guidanc rais thought
decent quarter although challeng remain legaci franchis face increas
competit investor low expect go earn consensu
impli revenu declin henc flat revenu growth still small victori
quarter question impact neulasta biosimilar lower repatha price
weaker aimovig launch metric neulasta sale benefit
purchas barda stabl market share seen like erod
meaning view remain cautiou repatha
discount volum growth expect outweigh price declin
earli oncolog asset bite kra combo highli anticip
investor see aacr updat kra buzz all-tim high
lack de-risk garner credit stock price point view howev
upcom data present could move quickli larger trial
upon evid clinic benefit could enhanc long-term growth profil
well legaci franchis face peak eros degre base busi eros
still unclear trend suffici neg dont see enough growth
driver off-set downward trend maintain equal weight pt
pipelin updat even approv april postmenopaus osteoporosi
dose escal data kra inhibitor present
also present dose escal data bcma bite
myeloma dose escal data psma bite prostat cancer
model adjust follow call adjust revenu
forecast respect similarli
revis non-gaap ep estim
respect page detail
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
equal weight despit improv pipelin
committ y/i dividend increas
improv margin compani revenu growth
outlook remain modest contribut
evolocumab kyproli alreadi reflect
estim view risk/reward profil
balanc expect market look greater
revenu accler cost save
pipelin adopt faster
anticip increas visibl biosimilar
threat neulasta/enbrel unlik materi
near-to-short term
launch slower expect
increas certainti time
biosimilar enbrel neulasta launch like
come signific price discount brand
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
